Latest Leadership News

Australian Vanadium Limited advances its vertically integrated vanadium strategy with key regulatory approvals, manufacturing expansions, and a new $10 million loan facility, positioning itself for major energy storage projects.

NewPeak Metals has completed acquisition of 100% ownership of the Las Opeñas exploration permits in Argentina, with drilling scheduled for early 2026. The company also advances drilling preparations at its Tansey Gold Project in Australia, supported by strong insider buying.

Alpha HPA Limited reports significant progress on its HPA First Project Stage 2 construction and secures $30 million funding, while signing new letters of intent with leading semiconductor OEMs.

Tasman Resources has progressed its exploration efforts at Lake Torrens and Parkinson Dam projects, backed by a recent $850,000 capital raise and strategic board changes.

Celsius Resources reports steady progress on its Maalinao-Caigutan-Biyog copper-gold project, supported by promising drilling outcomes and critical bridge financing. The company also advances social and environmental initiatives while preparing for operational readiness.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.

Integral Diagnostics reports a robust FY25 with revenue climbing 33.7% to $628 million, driven by successful Capitol Health merger integration and strong growth in teleradiology. CEO Dr Ian Kadish announces retirement after eight transformative years.

Green360 Technologies has independently verified its Eco-Clay product as a high-performance, low-carbon cement substitute made from kaolin waste, poised to disrupt Australia’s $3.5 billion cement market.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.